Qbtech to Provide $4M of Free FDA-Cleared ADHD Testing for Former Done Patients Seeking Re-evaluation
2024年7月15日 - 11:15PM
ビジネスワイヤ(英語)
Following Telehealth Company’s Fallout, Global
Leader in Evidence-based Objective ADHD Testing Technology Seeks to
Ease Diagnosis Concerns of Former Done Patients
In response to the recent arrests of Done founder Ruthia He and
clinical leader David Brody for the company’s alleged stimulant
prescription practices, Qbtech, the global leader in objective ADHD
testing, announced today it is waiving testing fees for former Done
patients. The free objective tests are designed to serve as a
safeguard for patients seeking a re-assessment to validate an ADHD
diagnosis completed by a Done virtual provider.
The allegations against Done’s executives put telehealth
practices and ADHD treatment under further scrutiny at a critical
time for U.S. health policy. As the DEA deliberates on telehealth
prescribing policies, this case highlights the worst possible
outcomes of telehealth care, potentially jeopardizing access to
care for millions of patients across the U.S.
“These purported prescribing practices by Done exacerbate the
critical need for quality measures in ADHD to assure robust
diagnostic decisions and effective treatment monitoring,” said Carl
Reuterskiold, CEO of Qbtech. “We’re facing a global shortage of
qualified clinicians to meet the growing demand for patients
seeking help, not to mention the medication shortage that has been
ongoing for over two years. Without objective quality measures,
supportive policies and vigorous processes, the promising potential
of telehealth ADHD care and other innovative care models is under
great threat.”
Objective data is necessary to deliver first-rate care and
address provider shortages while ensuring a scalable clinical
process that is well-documented, unbiased, and effective for
ongoing treatment monitoring. Advanced evidence-based technology to
support standard subjective assessments for ADHD has been proven in
several studies to deliver the same high-quality results across all
care settings. More than 12,000 clinicians globally use this type
of measurable data to inform their decisions, adding a level of
confidence for clinicians and assurance for patients.
“We have been focused on high-quality tests and processes in
ADHD care for more than 20 years, having administered over 1
million patients tested, 100,000 of whom were supported via
telehealth,” added Carl Reuterskiold. “The CDC estimates that as
many as 50,000 former Done patients may face disruption to their
care, with many needing to seek re-evaluation from a new provider
to continue treatment. By offering free tests to providers tasked
with re-evaluating diagnoses, we aim to provide these patients with
evidence-based measurements to ensure an accurate re-assessment of
their symptoms.”
As a testament to Qbtech’s mission to improve the lives of those
with ADHD, the company is offering one free test per patient
through Sept. 30, 2024. Test credits will be applied to providers’
Qbtech customer accounts to use when re-evaluating Done patients.
For additional details on the program and to register, visit
https://www.qbtech.com/let-us-support-you-in-helping-former-done-patients/.
About Qbtech
Founded in 2002, Qbtech is a privately-owned Swedish company
that has developed leading solutions and products for improving the
identification, diagnosis, treatment, and follow-up of patients
living with ADHD. Qbtech has operations in 14 countries and has
offices in Stockholm, Houston, and London. Qbtech is an
award-winning company recognized for its innovation, most recently
winning the 2022 HSJ Partnership Award for the ‘Best Mental Health
Partnership with the NHS.’ For more information about Qbtech, visit
www.qbtech.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240715327982/en/
Hilari Barton, Trevelino/Keller Hnbarton@trevelinokeller.com
404-214-0722 x 130